JPRN-jRCTs041180079已完成2 期
Phase II study of intraperitoneal paclitaxel combined with S-1 plus cisplatin for advanced gastric cancer with peritoneal metastasis - S-1/CDDP + IP PTX Phase 2 (SP + IP PTX)
Kodera Yasuhiro0 个研究点目标入组 53 人开始时间: 2019年3月11日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 53
研究概览
简要总结
S-1/cisplatin plus intraperitoneal paclitaxel for gastric cancer with peritoneal dissemination was suggested to be safe and effective.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 75age old（—）
- 性别
- All
入选标准
- •1) Histologically proven unresectable or recurrent gastric adenocarcinoma
- •2) Peritoneal metastasis
- •3) No prior chemotherapy
- •4) Adequate bone marrow function
- •5) Eastern Cooperative Oncology Group performance status 0-1
- •6) An expected survival period of more than 3 months
- •7) Written informed consent.
排除标准
- •1) Metastasis to distant organ sites (such as the liver, lungs or bone)
- •2) Other active concomitant malignancies
- •3) other severe medical conditions; pregnant
- •4) unwilling to practice contraception during the study, or lactating female
研究者
相似试验
进行中（未招募）
1 期
Paclitaxel for the Treatment of Gastric or Gastroesophageal CancerClinical Stage IV Gastric Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastric Cancer AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVB Gastric Cancer AJCC v8Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8Metastatic Gastric AdenocarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaPathologic Stage IV Gastric Cancer AJCC v8Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8Peritoneal CarcinomatosisPostneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8NCT04220827M.D. Anderson Cancer Center27
已完成
2 期
Phase II study of intraperitoneal paclitaxel combined with S-1 plus cisplatin for advanced gastric cancer with peritoneal metastasisgastric cancer with peritoneal metastasisJPRN-UMIN000023000agoya University50
已完成
2 期
Phase II study of intraperitoneal paclitaxel combined with S-1 plus oxaliplatin as second-line chemotherapy for advanced gastric cancer with peritoneal metastasisgastric cancer with peritoneal metastasisJPRN-UMIN000012836The University of Tokyo50
已完成
2 期
Phase II study of intraperitoneal paclitaxel combined with S-1 plus oxaliplatin for advanced gastric cancer with peritoneal metastasisgastric cancer with peritoneal metastasisJPRN-UMIN000012834The University of Tokyo50
已完成
2 期
Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine CarcinosarcomaUterine CarcinosarcomaNCT00687687Sanofi22